Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition

1. A method for manufacturing a sustained release drug-delivery composition, comprising:

providing at least a pharmaceutically active composition dissolved in an aqueous solution;

providing a hydrophobic matrix comprising at least a hydrophobic solid component and a hydrophobic liquid component, wherein the hydrophobic matrix is formed by mechanical treatment of the hydrophobic solid component and the hydrophobic liquid component, said mechanical treatment comprising repeated pressing and folding, wherein the hydrophobic matrix is kept in a non-molten state throughout the mechanical treatment;

mixing the hydrophobic matrix and the pharmaceutically active composition dissolved in an aqueous solution to form a paste-like or semi-solid drug-delivery composition, said mixing comprising repeated pressing and folding of the hydrophobic matrix and the pharmaceutically active composition to form the paste-like or semi-solid drug-delivery composition, wherein the pressing applies a pressure of not more than 10 8 N·m −2 , wherein the hydrophobic matrix is kept in a non-molten state throughout the mixing; and

wherein the pharmaceutically active composition dissolved in an aqueous solution comprises a pharmaceutically active compound selected from the group consisting of humanized monoclonal antibodies and human monoclonal antibodies.

2. The method according to claim 1 , wherein the pharmaceutically active composition comprises at least one excipient selected from the group consisting of monosaccharides, disaccharides, oligosaccharides, polysaccharides, hyaluronic acid, pectin, gum arabic and other gums, albumin, chitosan, collagen, collagen-n-hydroxysuccinimide, fibrin, fibrinogen, gelatin, globulin, polyaminoacids, polyurethane comprising amino acids, prolamin, protein-based polymers, copolymers and derivatives thereof, and mixtures thereof.

3. The method according to claim 1 , wherein the pharmaceutically active composition comprises at least a pharmaceutically active compound without any excipients.

4. The method according to claim 1 , wherein the forming of the paste-like or semi-solid drug-delivery composition includes repeated cycles of pressing and folding, in an algorithmic manner, of the mixture of the hydrophobic matrix and the pharmaceutically active composition.

5. The method according to claim 1 , further comprising:

forming the drug-delivery composition into an applicable form.

6. The method according to claim 1 , wherein active cooling is used in order to keep the hydrophobic matrix in a non-molten state throughout the repeated pressing and folding.

7. The method according to claim 1 , wherein the temperature of the pharmaceutically active composition is kept below 60° C. during repeated pressing and folding.

8. The method according to claim 1 , wherein the temperature of the pharmaceutically active composition is kept below 50° C. during repeated pressing and folding.

9. The method according to claim 1 , wherein the temperature of the pharmaceutically active composition is kept below 45° C. during repeated pressing and folding.

10. The method according to claim 1 , wherein the temperature of the pharmaceutically active composition is kept below 37° C. during repeated pressing and folding.

11. The method according to claim 1 , wherein the pharmaceutically active composition dissolved in an aqueous solution is added step-wise during mixing.

12. A method for manufacturing a sustained release drug-delivery composition, comprising:

providing at least a pharmaceutically active composition dissolved in aqueous solution;

providing at least a hydrophobic solid component;

providing at least a hydrophobic liquid component;

simultaneous mixing of at least the pharmaceutically active composition dissolved in an aqueous solution, the hydrophobic solid component, and the hydrophobic liquid component to form a paste-like or semi-solid drug-delivery composition, said mixing comprising repeated pressing and folding, wherein the pressing applies a pressure of not more than 10 5 N·m −2 , wherein the hydrophobic solid component is kept in a non-molten state throughout the mixing; and

wherein the pharmaceutically active composition dissolved in an aqueous solution comprises a pharmaceutically active compound selected from the group consisting of humanized monoclonal antibodies and human monoclonal antibodies.

13. The method according to claim 12 , wherein active cooling is used in order to keep the hydrophobic solid component in a non-molten state throughout the mixing.

14. The method according to claim 12 , wherein the temperature of the pharmaceutically active composition is kept below 60° C. during repeated pressing and folding.

15. The method according to claim 12 , wherein the temperature of the pharmaceutically active composition is kept below 50° C. during repeated pressing and folding.

16. The method according to claim 12 , wherein the temperature of the pharmaceutically active composition is kept below 45° C. during repeated pressing and folding.

17. The method according to claim 12 , wherein the temperature of the pharmaceutically active composition is kept below 37° C. during repeated pressing and folding.

18. The method according to claim 12 , wherein the mass ratio of the hydrophobic solid component to the hydrophobic liquid component is below 2.8:1.